| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Centro de Regulación Celular y Patología "Joaquín V. Luco," Millennium Institute of Fundamental and Applied Biology, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
1-anti-chymotrypsin,8
heparan sulfate proteoglycans,9,10
laminin,11
and acetylcholinesterase,12,13
among others. Alterations in AChE expression and distribution have been reported in AD brains.14-16
In fact, neuronal cell death in early stages of AD is related to the cholinergic system.17
Transgenic overexpression of human AChE in mice induces a progressive cognitive deterioration suggesting that upsetting cholinergic balance may by itself cause progressive memory decline in mammals.18-20
On the other hand, experiments in our laboratory have demonstrated that AChE promotes Aß peptide fibrils assembly in vitro21
and biochemical, physical, and morphological data strongly suggest that an amyloid-AChE complex is formed when AChE accelerates the assembly of Aß peptides.22
Such complexes were both Th-T fluorescence-positive and AChE activity-positive.23
More important those complexes were more toxic for primary cultured chick retina neurons and PC12 cells than Aß fibrils lacking AChE.24
Interestingly, the toxicity of the Aß-AChE complex was also dependent on the AChE concentration present in the complexes.25,26
All these evidences are consistent with the possibility that local increments of AChE, as those present in AD brains,12
should play a role in the neurodegeneration and cognitive deterioration observed in AD.14,27
Our hypothesis implies that AChE plays a role in the pathological changes observed in AD by promoting amyloid formation and stability, astrocytosis, and neurotoxicity. We decided, therefore, to evaluate and to compare in vivo the neurotoxicity of both Aß fibrils and Aß-AChE complexes. To perform these studies, we injected Aß fibrils and Aß-AChE complexes bilaterally in the rat dorsal hippocampus and the resulting neuropathological changes were studied. Results indicate that rats injected with Aß-AChE complexes in the hippocampus form amyloid deposits that seem bigger in size than those observed in matched controls injected with the same amount of Aß peptide, suggesting that endogenous rat Aß may became incorporated into the amyloid deposits. The injection of Aß-AChE complexes also results in the appearance of Alzheimer-like lesions in rat brain, and in all cases, the toxicity of the Aß-AChE complex depends on the amount of enzyme present in the complexes.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Aß peptide corresponding to residues 1 to 40 of the human wild-type sequence (Aß1-40) was obtained from Bachem (Torrance, CA) and the rat Aß1-40 peptide was obtained from Genemed Biotechnologies, Inc. (San Francisco, CA).
AChE Purification
Tetrameric G4 AChE form (sedimentation coefficient, 10.7 S) was purified from bovine caudate nucleus, using acridine affinity chromatography as previously described.27 Both specific activity (6000 U/mg protein) and staining intensity after sodium dodecyl sulfate-polyacrylamide gel electrophoresis28 were used to verify purity. AChE activity was determined by the method of Ellman and colleagues.29
Aß Fibril Formation
Aß fibrils were formed in a turbidity assay as previously described.23,24 Briefly, Aß peptide stock solution was prepared by dissolving freeze-dried aliquots of Aß1-40 in dimethyl sulfoxide (DMSO) at 15 mg/ml (3.5 mmol/L). An aliquot of this stock solution equivalent to 70 nmol of Aß peptide was added to aqueous buffer (725 µl total volume; 0.1 mol/L Tris-HCl, pH 7.4). For the aggregation assay in the presence of AChE, an identical aliquot of the stock solution (70 nmol) was added to a buffer containing AChE (100 nmol/L) at a final molar ratio of AßµAChE = 1000:1. The solutions were stirred continuously (1350 rpm) at room temperature for 48 hours and then left at 4°C for another 48 hours. Aggregation was measured by turbidity at 400 nm against a buffer blank. Amyloid fibrils obtained were characterized by Congo Red (CR) binding.
CR-Binding Assay
Fibril aliquots were added to a solution containing 25 µmol/L CR solution, 100 mmol/L phosphate buffer (pH 7.4), and 150 mmol/L NaCl in a final volume of 960 µl, and incubated for 30 minutes at room temperature.23 Absorbance was measured at 480 nm and 540 nm, and CR binding was determined by CR (concentration) = (A540/25,295) – (A480/46,306).30
ß-Amyloid Disaggregation Assays
One hundred µmol/L of Aß fibril suspensions were formed as described above either in the absence or the presence of 100 nmol/L AChE purified from bovine brain. Then, mouse laminin from Englebreth-Holm-Swarm tumor (Sigma L-2020 or Gibco catalog no. 23017-015; in 20 mmol/L Tris-HCl, 150 mmol/L NaCl, pH 7.2) was added to the fibril suspensions at a final laminin concentration as indicated in the legend of Figure 6
. Th-T measurements were taken from 4-µl sample aliquots (added to 500 µl of 50 mmol/L phosphate buffer, pH 6.0, containing 15 µl of 0.1 mmol/L Th-T) at indicated incubation time points by monitoring fluorescence at 
Ex = 450 nm and Em = 485 nm as described previously.21,23
|
Assembled fibrils were washed four times with phosphate-buffered saline (PBS) at 14,000 rpm for 30 minutes to remove soluble peptide and AChE. Pellets were finally resuspended in artificial cerebrospinal fluid (ACF) at a concentration of 2.3 µg/µl Aß peptide. Aliquots were mixed with a denaturing buffer and subjected to Tris-Tricine sodium dodecyl sulfate-polyacrylamide gel electrophoresis31 to quantify Aß peptide present into the fibrils by densitometry scanning. An Aß peptide stock of known concentration was used as standard. Data was processed by a GS365W program from Hoeffer Scientific Instruments (San Francisco, CA). Before the injection treatment, we followed amyloid formation by turbidity at 400 nm and CR binding. Similar methods were used during Aß fibril formation. The final products were analyzed using CR fibril staining under polarized light as well as by protease resistance assay (data not shown). All these assays did not show any apparent difference in the characteristic of the final amyloid product used for intracerebral injections.
Electron Microscopy of Amyloid Fibrils
The amyloid fibrils formed in turbidity assays were examined by electron microscopy. The fibrils were placed on Formvar carbon-coated 300-mesh nickel grids and negatively stained with 1% phosphotungstic acid solution for 1 minute. Grids were examined under a Phillips EM-300 electron microscope at 60 kV.21
Surgical and Injection Protocol
Male Sprague-Dawley rats (280 to 320 g; 3 months old) were anesthetized with Equitesin (2.5 ml/kg), and injected bilaterally into the upper leaf of dentate gyrus in dorsal hippocampus (–3.5 mm anteroposterior, ±2.0 mm medial-lateral, –2.7 mm dorsal-ventral from the dura, according to bregma)32 stereotaxically with a 10-µl Hamilton syringe with 27-gauge stainless steel needle. The injection is medial to granule layer and ventral to hippocampal fissure. The animals were injected bilaterally with 3 µl (at a rate of 0.5 µl/minute) of in vitro assembled Aß fibrils formed in the presence (n = 9) or absence of AChE (n = 9), which is equivalent to 7 µg of Aß peptide or Aß-AChE complex into each hippocampus. Control animals were injected with an identical volume of ACF (n = 6). Two (n = 3) and eight (n = 6) weeks later, animals were fixed by intracardiac perfusion to perform histochemical procedures (see below).
Surgical and Infusion Protocol
Sprague-Dawley rats (280 to 320 g) were anesthetized with Equitesin (2.5 mg/kg, i.p.) and then rats were placed on a stereotaxic apparatus. These animals were with implanted a 27-gauge double cannula at the dorsal hippocampus under the coordinates mentioned above. Through a polyethylene hose, each cannula was connected to a 200-µl Alzet 2002 miniosmotic pump (Alza Corp., Mountain View, CA), which releases its content to a rate of 0.5 µl/hour. The pumps were placed under the skin back the head toward the rat shoulder. The pumps were charged with both soluble Aß1-40 peptide (0.75 µg/µl) and with AChE (0.272 µg/µl), final concentration in PBS to molar ratio of 1:200 (total volume, 200 µl). Fourteen days after this procedure, in the case of Figure 5
, the procedure take 4 weeks, rats were fixed by perfusion with 4% paraformaldehyde and coronal brain sections were conducted for immunohistochemical analysis.
|
Animals were anesthetized with Equitesin (2.5 ml/kg. i.p.) and injected with heparin (4 USP/kg, i.p.) to inhibit blood coagulation before perfusion. To study the evolution of amyloid deposits, rats were fixed at day 2 and 8 weeks after injection to visualize the evolution of amyloid deposits. Then they were perfused through the heart with perfusion buffer33 containing 0.1% sodium nitrite, followed by fixation with 4% paraformaldehyde in 0.1 mol/L phosphate buffer (PB) for 30 minutes. Brains were removed from the skulls and postfixed in the same fixative for 3 hours at room temperature, followed by 10% sucrose in PB at 4°C overnight. After fixation, brains were coded to ensure unbiased processing and analysis. The brains were then cut into 50-µm coronal sections with a cryostat (Leitz 1900) at –20°C, from bregma –1.8 mm to bregma –4.8 mm.32 Sections from the same brain were divided into six groups for analysis by the following procedures: Nissl staining (0.3% cresyl violet); immunohistochemical staining for glial fibrillary acidic protein (GFAP), laminin, and Aß peptide; and CR and Th-S for specific amyloid staining.
Immunohistochemical Staining
Free-floating immunohistochemical procedure was performed as previously described.34 Washing and dilution of immunoreagents was performed with 0.01 mol/L PBS with 0.2% Triton X-100 (PBS+T) throughout the experiments, and two PBS+T washes were performed after incubation with each antibody incubation. All three immunohistochemical procedures for each sample were performed simultaneously. Sections were pretreated with 0.3% H2O2 for 30 minutes to reduce endogenous peroxidase activity followed by treatment with 5% normal goat serum (DAKO, Carpinteria, CA) at room temperature for 1 hour to avoid nonspecific binding. GFAP, laminin, and Aß detection was performed using the following antibodies: rabbit anti-GFAP polyclonal antibody (1:500) (DAKO), rabbit anti-laminin (1:60), and rabbit anti-Aß1-40 (1:100) (Sigma Chemical Co., St. Louis, MO) incubated overnight at 4°C. A horseradish peroxidase-conjugated goat anti-rabbit IgG second antibody was used in all three cases (1:600), incubated for 1 hour at room temperature. The staining was developed by incubation for 15 minutes with 0.6% diaminobenzidine followed by addition of H2O2 and incubation for 4 minutes. After immunostaining, all sections were mounted on gelatin-coated glass, air-dried, dehydrated in ascending concentrations of ethanol, cleared with xylene, and coverslipped with Canada balsam (Merck, Darmstadt, Germany).
Nissl, CR, and Th-S Fluorescence Staining
Mounted sections were defatted in xylene and hydrated in ethyl alcohol and water series. Nissl staining (cresyl violet) was performed as previously described.33 CR staining using alkaline CR methods was performed as previously described.35 Th-S staining was performed as described by Elghetany and Saleem.34
Image and Statistical Analysis
All histological and immunohistochemical images were acquired from a Zeiss Axioplan microscope with a 35-mm camera system. To analyze all plaque-like deposits in one field, x10 and x20 optical magnifications were used. The pictures were digitalized in a Nikon Coolscan III Scanner, and each image was routed into a PC-compatible microcomputer via Adobe-Photoshop program (5.5). Once digitalized, the images were analyzed with Scion Image public domain software (Scion Image for Windows ß 4.02, on the internet at http://www.scioncorp.com). Custom macro subroutine was used to calculate positively stained areas, of both immunopositives staining for Aß Th-S-fluorescence and CR-positive deposits. The same slides were analyzed single blind by two different investigators to ensure that trends were independent of individual bias. Serial coronal sections of the hippocampus were performed between the coordinates in an anteroposterior location to the injection site. The parameter measured was the positive area stained in six 50-µm-thick sections per rat per assay. Results from this analysis revealed the average of total area of the deposit. Analysis of number of cells, GFAP and laminin staining area, and GFAP intensity were measured with SigmaScan Pro software. Data from the image analysis macros were exported to a Sigma Plot file for statistical analysis. Results were expressed as mean ± SE. Statistical significance was determined by one-way analysis of variance.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
A specific antibody against the Aß peptide revealed successful injection of Aß fibrils into the dorsal hippocampus. Anti-Aß immunohistochemistry showed clear accumulation of Aß-positive deposits after intrahippocampal injection of Aß fibrils assembled with and without AChE. These deposits were observed in animals after 2 (Figure 1, A and B)
and 8 weeks (Figure 2
, D and G). Significant differences in the size of the deposits between both treatment groups were observed after 8 weeks of treatment using three different staining methods, anti-Aß antibody, thioflavine S, and CR (Figure 2J)
. In fact, animals examined at 2 weeks showed similar size of the Aß immunopositive areas with both injection treatments (Figure 1G)
, however, when animals were examined after 8 weeks of injection, a significant increase in the size of Aß-immunopositive area was observed in the case of animals injected with Aß-AChE complexes. This was evident after performing a digital quantification of the hippocampal areas stained with the anti-Aß antibody, which indicated almost a threefold increase of amyloid load in animals co-injected with Aß-AChE complexes compared with Aß (Figure 2J)
. Control animals injected with an unrelated peptide sequence derived from the ß-APP gave no specific amyloid staining (data not shown).
|
|
), in a similar way to very dense amyloid cores observed in AD lesions36,37
with the same pattern of anti-Aß staining in both treatment groups (compare Figure 1, C and D
, with A and B, respectively; and Figure 2, E and H
, with D and G, respectively). However, in all animals injected with Aß-AChE complexes, examined at 8 weeks after injection, amyloid deposits were larger in size with respect to animals injected with Aß fibrils assembled alone (Figure 2, E
versus H), confirming the results obtained with anti-Aß immunostaining (see also for digital quantification, Figure 2J
). Control animals injected with vehicle alone were completely negative for amyloid-specific staining (Figure 2
; A to C). In general, samples were observed under cross-polarized light microscopy after CR staining under polarized light is normally used, two kinds of positive staining are observed, one of these corresponds to an apple green birefringence, and the other, to a compact stellate staining, resembling Maltese crosses; the difference in staining is however poorly understood.38
Aß-positive deposits observed in both groups proved to be positive for CR staining (Figure 1, E and F
; Figure 2, F and I
), CR amyloid deposits were indicative of fibrillar amyloid deposition. In these cases, the congophilic aggregates were similar in size and stained with CR showing a compact congophilic material rounded by apple green birefringent deposits 2 weeks after injection (Figure 1G)
. However, in animals examined 8 weeks after injection, amyloid deposits showed differences between both groups. Rats injected with the Aß-AChE complexes exhibit amyloid deposits in which CR Maltese crosses are easily distinguished on microscopic observation (Figure 2I
, inset), apple green birefringent deposits were also present. Those animals injected with Aß fibrils only showed green apple birefringent deposits corresponding to amyloid, and they did not exhibit Maltese crosses (Figure 2F
, inset). AD lesions have been well characterized in terms of this feature, and the CR Maltese cross staining has been recognized in these particular lesions.38,39
The fact that both groups exhibit amyloid deposits with these subtle differences suggests that the presence of AChE in the amyloid plaques makes the difference. AChE Accelerates Aggregation of Rat Aß
The fact that 8 weeks later the animals injected with Aß-AChE complexes showed an increment in the size of the Aß deposit suggests that the endogenous rat Aß peptide might be recruited to the newly formed plaque, probably through the influence of AChE. To evaluate whether AChE was able to induce in vitro the rat Aß peptide assembly in Alzheimer-type of amyloid aggregates, a synthetic rat Aß1-40 peptide (Figure 3A)
was used to study the effect of pure AChE in an Aß aggregation assay. Turbidity assays show that AChE induces rat Aß peptide to form amyloid fibrils in an AChE concentration-dependent manner (Figure 3B)
as shown by CR-binding measurements (Figure 3C)
to confirm that the aggregates correspond to amyloid. An electron microscopic study was performed to establish the formation of amyloid fibrils from the assembly of rat Aß1-40 peptide, in the presence and absence of increasing AChE. Figure 3D
shows, that AChE stimulates the amyloid fibril formation of the rat Aß1-40 peptide in comparison with the rat Aß peptide alone.
|
Laminin is a normal component of the extracellular matrix, which is found in the brain lesions of patients with AD and Down’s syndrome.40,41
To further characterize the lesions induced by the injected amyloid, we performed immunohistochemical analysis using an anti-laminin polyclonal antibody (Figure 4)
. At 2 weeks after injection, the characterization of injected amyloid deposits formed with Aß alone or Aß-AChE complexes showed little laminin immunoreactivity along the dentate gyrus (Figure 4
; A to C). Laminin stain changes considerably 8 weeks after injection. Animals injected with Aß fibrils alone showed very little laminin immunostaining associated to amyloid deposits (Figure 4D)
, but lesions induced by Aß-AChE complexes showed an increased laminin immunoreactivity associated with the core of amyloid deposits in all of the animals examined after 8 weeks (Figure 4E
, arrow), suggesting that more laminin was attracted to the Aß-AChE complexes, as a result of the laminin increases observed after injury.11
The quantification of the laminin staining area in the upper leaf of the dentate gyrus shows that the presence of Aß-AChE complexes induces a clear increase in laminin immunoreactivity 8 weeks after injection (Figure 4F)
, in the region associated with the amyloid deposit (Figure 4E)
. To characterize the interaction between laminin and the induced amyloid deposits, Aß1-40 soluble peptide was infused concomitantly with AChE into the hippocampus. After 2 weeks of infusion, animals were sacrificed and coronal brain sections were analyzed for the presence of amyloid deposits with Th-S and adjacent sections were submitted to laminin detection (Figure 5)
. As observed in Figure 5A, a
big Th-S-positive plaque was detected in the animal. Interestingly, surrounding the amyloid plaque a clear laminin staining was observed (Figure 5B
, arrowheads), which corresponds to hippocampal neurons with increased laminin immunoreactivity (Figure 5B
, arrows in the inset). The results suggest that laminin is induced in adult rat brain by injury, in the boundaries of the amyloid plaque.
|
One possible explanation for the presence of laminin in the amyloid deposits that contain AChE may be related to the fact that laminin was induced and secreted toward the amyloid deposits, to depolymerize amyloid fibrils, as has been previously reported.42-44
However, in view that an extensive amyloid deposition was observed in brains injected with Aß-AChE complexes, we analyzed the ability of laminin to disaggregate AChE-containing amyloid deposits in vitro. For such a purpose we prepared Aß1-40 fibrils either in the presence or absence of AChE (molar ratio, AChE:Aß = 1:1000). In Figure 6
, 200 nmol/L of laminin completely disaggregated 100 µmol/L of Aß fibrils in 2 hours at room temperature (Figure 6
, white circles) but in the presence of 100 nmol/L of AChE this effect was not observed (Figure 6
, white inverted triangles). Aß fibrils and Aß-AChE complexes remained unchanged in the absence of laminin (Figure 6
, black circles and inverted triangles, respectively). The inset of Figure 6
shows the Aß fibril (Th-T fluorescence) dependence on laminin concentration in the presence or absence of AChE at 2 hours of incubation.
Aß and Aß-AChE Complexes Induce GFAP-Positive Astrocytes, but Only the Aß-AChE Complexes Induced Reactive Hypertrophic Astrocytes
It is well known that reactive astrocytes are an indication of inflammatory processes that occur in response to brain injury.45
In the present study, we used GFAP immunoreactivity to visualize the cellular response of glial cells to the injection treatments. Reactive astrocytes were observed near to the injection site at 2 and 8 weeks after injection (Figure 7)
. In the case of animals injected with Aß fibrils the astrocytic responses returned to the basal levels after 8 weeks of injection (Figure 7, A and C)
in a similar manner as observed after Aß25-35 fragment injection.46
Animals injected with Aß-AChE complexes showed GFAP staining closely associated to the amyloid deposits (see below) (Figure 7, B and D)
. The GFAP-stained area in the injection site was quantified (Figure 7E)
. As observed in the graph, Aß fibrils and Aß-AChE complexes induced an astrocytic response after 2 weeks of treatment; after 8 weeks of treatment, the astroglial response area decreased importantly in the Aß fibrils injected rats, in contrast to those animals injected with Aß-AChE complexes, which maintained an increased GFAP immunoreactivity area (Figure 7E)
. In all of the cases sections were obtained at comparable distances from the injection site. The activation of astrocytes was better observed in Figure 8
. The injection of either Aß fibrils or Aß-AChE complexes did induce some astrocytosis 2 weeks after the injection (Figure 8, B and C)
; however, at 8 weeks after the injection, the astrogliosis apparently diminished in Aß fibrils in injected rats (Figure 8D)
more dramatically than in rats injected with Aß-AChE complexes, which show hypertrophic highly reactive astrocytes (Figure 8E)
. The analysis of the upper leaf of the dentate gyrus of the hippocampus allowed us to quantify the reactive astrocytes as GFAP-positive cells in that region. Eight weeks after injection the number of reactive astrocytes augmented 200% in animals injected with Aß-AChE complexes as compared with animals injected only with Aß fibrils (Figure 8F)
. Likewise, the GFAP intensity in the astrocyte soma was measured. Animals injected with Aß-AChE complexes showed a significant increment in the intensity of GFAP immunostaining compared with those animals injected with Aß fibrils 8 weeks after injection (Figure 8G)
. Finally, we measured the size of the astrocyte soma found in the dentate gyrus; in agreement with the previous results, after 8 weeks of treatment, reactive astrocytes present an increase in the size of the cellular soma in response to Aß-AChE complexes (Figure 8H)
, confirming the presence of hypertrophic reactive astrocytes in rats injected with Aß-AChE complexes. All of the treatments showed a higher astrogliosis than the control (ACF+DMSO) (Figure 8A)
, however, only the reactive response triggered by the Aß-AChE complex increased with time. These results suggest that the return to basal levels of the astrocytic response is delayed in animals injected with Aß-AChE complexes, probably because of the presence of a more toxic environment than the one of animals injected with Aß fibrils alone.
|
|
Neuronal cell loss was examined by using a specific neuronal stain, cresyl violet, which did not stain glial cells.33
Sections of the dorsal hippocampal region stained with cresyl violet (Nissl stain) showed that the injection of Aß fibrils, assembled alone or in the presence of AChE induces loss of granular neurons involving mainly the upper leaf of the dentate gyrus near the injection site (Figure 9
; C to F), in contrast to intact (Figure 9A)
, mock injected (ACF, picture not shown) or to control injected rats (ACF plus DMSO) (Figure 9B
, control), which showed no degeneration in the same area (Figure 9B)
. This latter observation indicates that neither the injection per se nor the mechanical procedures accompanying surgery induce neuronal degeneration or cell death. Neuronal cell loss was visualized by the thickness or the absence of the Nissl staining in the dentate gyrus of the hippocampus. The number of neuronal losses appears similar in animals treated with Aß fibrils and Aß-AChE complexes during the first 2 weeks, however the total number of neurons in treated animals decreased in almost 50% respect to the control (Figure 9, C and D
, respectively). However, after 8 weeks of injection a major degenerative effect was observed in animals injected with Aß-AChE complexes in comparison with those injected with Aß fibrils alone (compare Figure 9, E
versus F). Coronal brain sections stained with Nissl staining of different animals were quantified and the number of neuronal cells present along the dentate gyrus estimated. Results are presented in Figure 9G
. It is clear that the injection of both Aß fibrils and Aß-AChE complexes, induces at 2 weeks, a significant neuronal cell loss (almost 50% of control animals), however, at 8 weeks after injection, the Aß-AChE complexes induced a further and more pronounces decrease in neuronal cell loss. These results indicate, again, that a more drastic effect of the Aß-AChE amyloid deposits was apparent at the level of the number of neurons present at the dentate gyrus of the hippocampus.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Our results are reminiscent of the previous studies carried by Snow and colleagues,39 in which they demonstrated plaque formation in vivo using co-infusion of Aß with heparan sulfate proteoglycans, moreover they found that Aß injected with the proteoglycan was more stable and more fibrillogenic than Aß injected alone.
In our study the presence of the Aß peptide was detected with a polyclonal antibody against the human Aß1-40 sequence, which recognized rat Aß in Western blot (data not shown). Interestingly, after 2 weeks of treatment, no differences in the size of amyloid deposits between animal groups were observed. However, 8 weeks after injection, amyloid deposits were significantly larger in animals treated with Aß-AChE complexes than those treated with Aß fibrils. These observations were confirmed by measuring the Th-S fluorescence-positive area. Because the starting material was the same for both treatment groups, it is conceivable that Aß-AChE complexes could recruit endogenous Aß peptide, because of the presence of AChE incorporated in amyloid fibrils. This possibility is likely, because, we have previously shown that AChE was able to accelerate the assembly of the Aß peptide into Alzheimer-type of amyloid fibrils.21 In fact, in the present work we were able to demonstrate that AChE was indeed able to promote rat Aß peptide aggregation into amyloid fibrils in vitro, despite the very low intrinsic aggregation capacity of the rat Aß peptide, because rat Aß peptide has three amino acid substitutions in relation to the human Aß sequence.47 Histological analysis of rat brain serial sections stained with CR showed that the injected material was congophilic and produced birefringence under polarized light. Notably, animals injected with Aß-AChE complexes exhibited the Maltese cross pattern within amyloid deposits, suggesting that this amyloid was somehow different from the one resulting from injection of Aß fibrils alone, and reminiscent of the real AD lesions. It is possible that these differences may be because of a different composition, originating from the incorporation of endogenous elements including proteins and metals.
The role of laminin in AD brains has been associated with the growth of neuronal processes.40 However, we and others had shown that laminin could be involved in the inhibition of amyloid formation in vitro48-50 and we had demonstrated that preformed amyloid fibrils could be depolymerize in vitro.42-44 The presence of laminin close to the amyloid deposits may indicate a sort of defense mechanism in which laminin may initiates the depolymerization of Aß fibrils, however, the fact that laminin remains associated to the amyloid deposits, without destroying them, may mean that in the presence of AChE, the amyloid fibrils became more resistant to the effect of laminin. This possibility was examined in vitro and proves to be true, ie, in the presence of AChE, Aß fibrils became resistant to laminin depolymerization.
To assess whether amyloid deposits induced neuronal cell death in rat brains, we examined serial tissue sections of the dentate gyrus using the Nissl technique. Two weeks after an acute injection, no morphological differences between both groups were found, and the extent of neuronal cell loss was concentrated in the upper leaf of dentate gyrus, and it was similar in both cases. The neuronal cell loss observed is similar in animals treated with Aß fibrils (2 and 8 weeks) and Aß-AChE complexes (2 weeks), showing more than 35% neuronal loss respect to controls, which is reminiscent of the neuronal cell loss in dentate and hippocampal fissure observed after human amyloid cores injection, at similar coordinates.51 However, at 8 weeks after injection, the Aß-AChE complexes induced a further and more pronounced decrease in neuronal cell loss (more than 50% cell loss). Similar results have been obtained previously in our laboratory using infusion models.52-54 Our finding indicates that the damage induced by the injection of Aß-AChE complexes was specific and not related to mechanical disruption. Some authors have suggested that the vehicle used to dissolve Aß peptide could be a determinant factor in the damage induced by the injection,55 in our study this possibility was ruled out, because we rinsed the Aß fibrils exhaustively and then they were resuspended in ACF before the stereotaxic injections were performed.
The mechanisms of in vivo toxicity of ß-amyloid are not completely understood, however there is evidence indicating that adult rats injected into the basal forebrain with the Aß peptide undergo a decrease in acetylcholine release from the hippocampus.56 Other authors have demonstrated that intracerebral injections of Aß1-40 in rat brain, determined neuronal cell loss in the cholinergic system, as well as an extracellular accumulation of AChE.57 Similar approaches have shown that the intracerebral administration of Aß1-42 produced toxic effects in cholinergic neurons as indicated by a decrease in choline acetyltransferase (ChAT) immunoreactive neurons in the basal forebrain together with a reduction in ChAT-positive axons in the cerebral cortex.58
In conclusion, our studies are consistent with the notion that Aß-AChE complexes trigger some of the neurodegenerative changes observed in AD brain, and that AChE may potentiate not only the amyloid deposition in vivo, but also the toxicity of the amyloid deposits. Finally, recent studies obtained with a double-transgenic mice that overexpress human AChE and APP are consistent with the results presented here, in fact, double-APP-AChE transgenic mice showed amyloid plaques earlier than those animals overexpressing APP alone.59
|
Footnotes |
|---|
Supported by the Centro de Regulación Celular y Patologia "Joaquín V. Luco"-Biomedicine (grant no. 13980001) and the Millennium Institute of Fundamental and Applied Biology (to N.C.I.).
Present address of A.E.R.: Facultad de Ciencias de la Salud, Universidad Diego Portales, Ejército 141, Santiago, Chile. Present address of C.M.: Laboratorio de Bioinformé, tica y expresión Génica, INTA, Universidad de Chile, Macul 5540, Santiago, Chile.
Accepted for publication February 15, 2004.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
1-antichymotrypsin in the brain amyloid deposits of the Alzheimer’s disease. Cell 1988, 52:487-501[Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
